Table 1 Key characteristics and findings of the included studies
References | Country | No. of patients | Age | Type | Non-cardiac surgery(n) | Type of stents | Time from PCI to surgery (months) | Bridging protocol | Non-MACE | Non-reoperation | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Success rate(95% CI) | Number | Success rate(95% CI) | |||||||||
Xia (2013) | China | 21 | 63 | Obs,Prosp | 21(100%) | DES | 6 | Initiated tirofiban 4.8 days prior to surgery; stopped tirofiban 4 h prior to surgery | 21 | 100% (83.9–100%) | 21 | 100% (83.9–100%) |
Walker (2017) | USA | 20 | 72 | Obs,Restrosp | 11(55%) | DES | 1.1 | Initiated tirofiban 3.5 days prior to surgery; stopped tirofiban 5.4 h prior to surgery | 18 | 90.0% (68.3–98.8%) | 20 | 100% (83.2–100%) |
Savonitto (2010) | USA | 30 | 65 | Obs,Prosp | 21(70%) | DES | 4 | Initiated tirofiban 4 days prior to surgery; stopped tirofiban 5 h prior to surgery | 30 | 100% (88.4–100%) | 30 | 100% (88.4–100%) |
Polito (2018) | Italy | 21 | 62 | Obs,Restrosp | 0(0%) | DES | 0,23 | Initiated tirofiban 3 days prior to surgery; stopped tirofiban 4 h prior to surgery | 20 | 95.2% (76.2–99.9%) | 21 | 100% (83.9–100%) |
Marcos (2011) | Netherlands | 36 | 66 | Obs,Restrosp | 21(58%) | Mixed(58%DES) | 2.6 | Initiated tirofiban 4 days prior to surgery; stopped tirofiban 4 h prior to surgery | 36 | 100% (90.3–100%) | 35 | 97.2% (85.5–99.9%) |
Servi (2016) | Italy | 87 | 67.4 | Obs,Restrosp | 59(68%) | 91% | 3.4 | Initiated tirofiban 3 days prior to surgery; stopped tirofiban 4 h prior to surgery | 85 | 97.7% (91.9–99.7%) | 87 | 100% (95.8–100%) |
Waldron (2017) | USA | 30 | 65 | Obs,Restrosp | 30(100%) | DES | Not mention | Used eptifibatide, not mention bridging details | 27 | 90.0% (73.5–97.9%) | 30 | 100% (88.4–100%) |
Rassi (2012) | USA | 100 | 63.2 | Obs,Restrosp | 29(29%) | Mixed(89%DES) | 5.8 | Initiated eptifibatide 5.3 days prior to surgery; stopped eptifibatide 7 h prior to surgery | 93 | 93.0% (86.1–97.1%) | 90 | 90.0% (82.4–95.1%) |
Morrison (2012) | USA | 19 | 65 | Obs,Restrosp | 6(32%) | DES | 3.5 | Initiated eptifibatide 2.6 days prior to surgery; stopped eptifibatide 10 h prior to surgery | 19 | 100% (82.4–100%) | 18 | 94.7% (74.0–99.9%) |
Barra (2016) | USA | 18 | 61.9 | Obs,Restrosp | 13(72%) | Mixed(89%DES) | 3.5 | Initiated eptifibatide 2.7 days prior to surgery; stopped eptifibatide 6 h prior to surgery | 18 | 100% (81.5–100%) | 17 | 94.4% (72.7–99.9%) |